John M Davis
Cited by
Cited by
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
S Leucht, A Cipriani, L Spineli, D Mavridis, D Örey, F Richter, M Samara, ...
The Lancet 382 (9896), 951-962, 2013
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
S Leucht, C Corves, D Arbter, RR Engel, C Li, JM Davis
The Lancet 373 (9657), 31-41, 2009
Norepinephrine in depressive reactions: A review
WE Bunney, JM Davis
Archives of General Psychiatry 13 (6), 483-494, 1965
A meta-analysis of the efficacy of second-generation antipsychotics
JM Davis, N Chen, ID Glick
Archives of general psychiatry 60 (6), 553-564, 2003
Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study
A Guidotti, J Auta, JM Davis, VDG Gerevini, Y Dwivedi, DR Grayson, ...
Archives of general psychiatry 57 (11), 1061-1069, 2000
A cholinergic-adrenergic hypothesis of mania and depression
DS Janowsky, JM Davis, MK El-Yousef, HJ Sekerke
The Lancet 300 (7778), 632-635, 1972
Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study
JR Hibbeln, JM Davis, C Steer, P Emmett, I Rogers, C Williams, J Golding
The Lancet 369 (9561), 578-585, 2007
Efficacy of divalproex vs lithium and placebo in the treatment of mania
CL Bowden, AM Brugger, AC Swann, JR Calabrese, PG Janicak, F Petty, ...
Jama 271 (12), 918-924, 1994
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
M Huhn, A Nikolakopoulou, J Schneider-Thoma, M Krause, M Samara, ...
The Lancet 394 (10202), 939-951, 2019
Physical health monitoring of patients with schizophrenia
SR Marder, SM Essock, AL Miller, RW Buchanan, DE Casey, JM Davis, ...
American Journal of Psychiatry 161 (8), 1334-1349, 2004
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
S Leucht, M Tardy, K Komossa, S Heres, W Kissling, G Salanti, JM Davis
The Lancet 379 (9831), 2063-2071, 2012
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.
MP Freeman, JR Hibbeln, KL Wisner, JM Davis, D Mischoulon, M Peet, ...
Journal of Clinical psychiatry 67 (12), 1954, 2006
Diagnosis and drug treatment of psychiatric disorders
DF Klein, JM Davis
Psychopharm Review 4 (6), 24, 1969
The Altman self-rating mania scale
EG Altman, D Hedeker, JL Peterson, JM Davis
Biological psychiatry 42 (10), 948-955, 1997
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials
SR Marder, JM Davis, G Chouinard
J Clin Psychiatry 58 (12), 538-546, 1997
A decrease of reelin expression as a putative vulnerability factor in schizophrenia
F Impagnatiello, AR Guidotti, C Pesold, Y Dwivedi, H Caruncho, MG Pisu, ...
Proceedings of the National Academy of Sciences 95 (26), 15718-15723, 1998
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis
C Rummel-Kluge, K Komossa, S Schwarz, H Hunger, F Schmid, ...
Schizophrenia research 123 (2-3), 225-233, 2010
Bulimia: Its incidence and clinical importance in patients with anorexia nervosa
RC Casper, ED Eckert, KA Halmi, SC Goldberg, JM Davis
Archives of General Psychiatry 37 (9), 1030-1035, 1980
Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine
V Uzunova, Y Sheline, JM Davis, A Rasmusson, DP Uzunov, E Costa, ...
Proceedings of the National Academy of Sciences 95 (6), 3239-3244, 1998
Moving the participation agenda forward
M Hill, J Davis, A Prout, K Tisdall
Children & society 18 (2), 77-96, 2004
The system can't perform the operation now. Try again later.
Articles 1–20